Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomization

Abstract excerpt

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently received Food and Drug Administration (FDA) approval for obesity management. However, the causal relationship between GLP-1RAs and psychiatric and neurodevelopmental conditions remains unclear. METHODS: We used Mendelian randomization (MR) to investigate the association between genetically proxied GLP-1RA exposure and 12 psychiatric...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Diabetes Treatment and Management
• Share to Genetic Associations and Epidemiology
• Share to Pharmacogenetics and Drug Metabolism